Details for Patent: 11,266,641
Which drugs does patent 11,266,641 protect, and when does it expire?
Patent 11,266,641 protects PALSONIFY and is included in one NDA.
This patent has thirty-two patent family members in twenty-seven countries.
Summary for Patent: 11,266,641
| Title: | Formulations of a somatostatin modulator |
| Abstract: | Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity. |
| Inventor(s): | Gerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler |
| Assignee: | Crinetics Pharmaceuticals Inc |
| Application Number: | US17/468,440 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 11,266,641
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-001 | Sep 25, 2025 | RX | Yes | No | 11,266,641 | ⤷ Start Trial | Y | TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION | ⤷ Start Trial | |||
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-002 | Sep 25, 2025 | RX | Yes | Yes | 11,266,641 | ⤷ Start Trial | Y | TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,266,641
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 123453 | ⤷ Start Trial | |||
| Australia | 2021341936 | ⤷ Start Trial | |||
| Canada | 3191084 | ⤷ Start Trial | |||
| Chile | 2023000627 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
